Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triple attack therapy
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
"Triple attack therapy" is a combination pharmaceutical regimen primarily used for the eradication of *Helicobacter pylori* infection, a common cause of peptic ulcers. This therapy typically consists of a proton pump inhibitor (such as omeprazole) to reduce gastric acid production, and two antibiotics, clarithromycin and metronidazole, to target and eliminate the *H. pylori* bacteria. The regimen is usually administered orally for a duration of 14 days.
- Other names
- omeprazole-Kasr El Aini Hospital-Helicobacter pylori infectiontriple attack therapytriple therapy
02
Targets
Bacterial 50S ribosomal subunitNeuraminidaseATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on triple attack therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triple attack therapy.